Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- Takeda to Discontinue Kenketu Albuminate amid Falling Demand
September 3, 2024
- METI Seeks 5.8 Billion Yen to Fund Biologic Manufacturing Technologies in FY2025
September 2, 2024
- MHLW to Set AI Limit for Atomoxetine’s Nitrosamine Impurities at 100 ng/Day
September 2, 2024
- Japan Panel OKs BMS ROS1 Inhibitor, Janssen Bispecific, JN.1-Targeted Nuvaxovid
September 2, 2024
- LDP Study Group Mulls Seeking More Budget for Immunoglobulins in FY2025
August 30, 2024
- FY2025 Budget Request Earmarks Funding to Systematize Collection of Drug Supply Info
August 30, 2024
- MHLW Seeks 19.8 Billion Yen for Launch of Pandemic Agency JIHS in April
August 30, 2024
- MHLW Requests Funds for Adding PMDA Reviewers, Subsidizing Advisory Fees in FY2025
August 29, 2024
- MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
- MHLW’s Tax Reform Request Not Yet Clear, HSC Debate Might Be a Cue
August 29, 2024
- LDP Health Division OKs MHLW’s FY2025 Budget Request
August 29, 2024
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- Trintellix, Vtama Get 2-Year Extension of Re-Examination Period
August 29, 2024
- Japan Doles Out Orphan Tags for 10 APIs, Pulls Status for Biogen’s MS Drug
August 29, 2024
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
- Panel Conditionally OKs Change to Allow Use of Abortion Pill at Clinics Without Beds
August 28, 2024
- Japan Panel Clears Amgen’s TED Med, Rexulti for Alzheimer’s Agitation and More
August 28, 2024
- High-Dose Mecobalamin Now in Line to Become Japan’s 1st ALS Med in 9-Plus Years
August 28, 2024
- MHLW Sets Global Health Vision to Enhance Drug Innovation Ecosystem
August 28, 2024
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…